23 Citations (Scopus)

Abstract

First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl- transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95%CI 1.085-177.056). These findings require confirmation. However, screening for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.

Original languageEnglish
Pages (from-to)376-378
Number of pages3
JournalInternational Journal of Tuberculosis and Lung Disease
Volume16
Issue number3
DOIs
Publication statusPublished - Mar 1 2012

Fingerprint

Uridine Diphosphate
Transferases
Tuberculosis
Liver
Pharmaceutical Preparations
Therapeutics
Incidence

Keywords

  • Anti-tuberculosis drug-induced hepatotoxicity
  • ATDH
  • NAT2
  • UGT1A1

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

@article{173f35ec08c44ff783dd2764378cdfdf,
title = "UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications",
abstract = "First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl- transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95{\%}CI 1.085-177.056). These findings require confirmation. However, screening for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.",
keywords = "Anti-tuberculosis drug-induced hepatotoxicity, ATDH, NAT2, UGT1A1",
author = "Chang, {J. C.} and Liu, {E. H.} and Lee, {C. N.} and Lin, {Y. C.} and Yu, {M. C.} and Bai, {K. J.} and Chen, {Hsiang Yin}",
year = "2012",
month = "3",
day = "1",
doi = "10.5588/ijtld.11.0404",
language = "English",
volume = "16",
pages = "376--378",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "3",

}

TY - JOUR

T1 - UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications

AU - Chang, J. C.

AU - Liu, E. H.

AU - Lee, C. N.

AU - Lin, Y. C.

AU - Yu, M. C.

AU - Bai, K. J.

AU - Chen, Hsiang Yin

PY - 2012/3/1

Y1 - 2012/3/1

N2 - First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl- transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95%CI 1.085-177.056). These findings require confirmation. However, screening for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.

AB - First-line drug treatment for tuberculosis (TB) is frequently associated with liver toxicity. The goal of this study was to examine the association between UDP-glucuronosyl- transferase 1A1 (UGT1A1) genetic variations and anti-tuberculosis drug-induced hepatotoxicity (ATDH). A total of 98 patients, including 17 patients with ATDH, were enrolled; compound UGT1A1*27 and UGT1A1*28 were associated with an increased risk for developing ATDH after adjusting for age (OR 13.859; 95%CI 1.085-177.056). These findings require confirmation. However, screening for genetic variations prior to TB treatment may reduce the incidence of ATDH and improve treatment adherence.

KW - Anti-tuberculosis drug-induced hepatotoxicity

KW - ATDH

KW - NAT2

KW - UGT1A1

UR - http://www.scopus.com/inward/record.url?scp=84863172644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863172644&partnerID=8YFLogxK

U2 - 10.5588/ijtld.11.0404

DO - 10.5588/ijtld.11.0404

M3 - Article

C2 - 22230213

AN - SCOPUS:84863172644

VL - 16

SP - 376

EP - 378

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 3

ER -